Hugh Young Rienhoff Jr.
Net Worth
Last updated:
What is Hugh Young Rienhoff Jr. net worth?
The estimated net worth of Dr. Hugh Young Rienhoff Jr. is at least $36,151,451 as of 3 Jan 2023. He owns shares worth $17,627,831 as insider, has earned $16,930,860 from insider trading and has received compensation worth at least $1,592,760 in Imago BioSciences, Inc..
What is the salary of Hugh Young Rienhoff Jr.?
Dr. Hugh Young Rienhoff Jr. salary is $530,920 per year as Chief Executive Officer & Director in Imago BioSciences, Inc..
How old is Hugh Young Rienhoff Jr.?
Dr. Hugh Young Rienhoff Jr. is 72 years old, born in 1953.
What stocks does Hugh Young Rienhoff Jr. currently own?
As insider, Dr. Hugh Young Rienhoff Jr. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Imago BioSciences, Inc. (IMGO) | Chief Executive Officer & Director | 489,526 | $36.01 | $17,627,831 |
What does Imago BioSciences, Inc. do?
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Hugh Young Rienhoff Jr. insider trading
Imago BioSciences, Inc.
Dr. Hugh Young Rienhoff Jr. has made 2 insider trades between 2022-2023, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 266,784 units of IMGO stock on 16 Dec 2022. As of 3 Jan 2023 he still owns at least 489,526 units of IMGO stock.
Imago BioSciences key executives
Imago BioSciences, Inc. executives and other stock owners filed with the SEC:
- Dr. Amy E. Tapper Ph.D. (54) Senior Vice President of Chemistry, Manufacturing & Controls and Non-Clinical Devel.
- Dr. Hugh Young Rienhoff Jr. (72) Chief Executive Officer & Director
- Ms. Jennifer Peppe (54) Senior Vice President of Clinical Operations